Roche Holding Ltd. just made its second bet on a new Alzheimer’s treatment. Investors who are now evaluating the Swiss pharmaceutical giant’s shares should remember that its managers take more of a long-term stance than many of the other noisy chest-thumpers in the industry. Widely known for its cancer-fighting drugs such as Avastin, Roche’s unit [...]